Resistance

As with all other anti-HIV drugs, strains of HIV that are resistant to FTC (emtricitabine, Emtriva) may emerge after a period of treatment. The emergence of drug-resistant strains coincides with a fall in the effectiveness of the drug. HIV can rapidly develop resistance to FTC if viral load is not suppressed below the limit of detection .

The M184V/I mutation, which is associated with resistance to 3TC (lamivudine, Epivir), is also the key resistance mutation for FTC.1 However, this mutation develops more slowly in people taking FTC.2

FTC is unlikely to have anti-HIV effect in people who have already developed resistance to 3TC. However, the M184V mutation can enhance the antiviral efficacy of other drugs such as AZT (zidovudine, Retrovir), because it slows the ability of the virus to develop resistance to them. The mutation does not affect susceptibility to other nucleoside reverse transcriptase inhibitors (NRTIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs).

No other mutations have been associated with high-level FTC resistance, including other NRTI and NNRTI mutations. However, the K65R mutation, which is associated with ddC (zalcitabine, Hivid) resistance, may slightly reduce the efficacy of FTC.

References

  1. Cahn P et al. Virologic efficacy and patterns of resistance mutations in ART-naïve patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multi-center clinical trial. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract P606, 2003
  2. Barroto-Esoda K et al. Lower incidence of the M184V mutation in ART naïve patients receiving combination therapy with emtricitabine (FTC) compared to lamivudine (3TC), results of a double blind equivalence trial. First International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, abstract LB-P21, 2001
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.